Patents Assigned to Chiesi Farmaceutici S.p.A.
  • Publication number: 20240199635
    Abstract: The present invention relates to compounds of general formula (I) inhibiting Discoidin Domain Receptors (DDR inhibitors), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful for instance in the treatment of many disorders associated with DDR mechanisms.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 20, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZi, Keith Christopher KNIGHT, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS, Ben Paul WHITTAKER
  • Publication number: 20240190847
    Abstract: The present invention relates to compounds of general formula (I) inhibiting DDR1 and DDR2. Particularly, the invention relates to compounds that are indoline derivatives, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of DDRs, in particular fibrosis.
    Type: Application
    Filed: March 25, 2022
    Publication date: June 13, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Laura CARZANIGA, Fabio RANCATI, Andrea RIZZI, Anna KARAWAJCZYK, Barbara Karolina WOLEK, Toby Matthew Grover MULLINS
  • Publication number: 20240190891
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: June 13, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Claudio FIORELLI, Barbara BERTANI
  • Publication number: 20240165203
    Abstract: The present invention relates to a combined therapy for use in treatment and prevention of treatment and prevention of brain injury, in particular ischemic and/or hypoxic brain lesions, including but not limited to hypoxic-ischemic encephalopathy, preferably in a neonatal subject either at term or at preterm.
    Type: Application
    Filed: March 25, 2022
    Publication date: May 23, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Bruno Pietro IMBIMBO, Gino VILLETTI, Fabrizio FACCHINETTI, Elisa LANDUCCI, Dalila MANGO
  • Publication number: 20240166651
    Abstract: The present invention relates to a compounds of general formula (I) inhibiting the JAK family of non-receptor tyrosine protein kinases (JAK1, JAK2, JAK3, and TYK2); methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of the JAK family non-receptor kinases; in particular for the treatment of various inflammatory disease including asthma, COPD and other respiratory diseases.
    Type: Application
    Filed: March 14, 2022
    Publication date: May 23, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Alessandro ACCETTA, Fabio RANCATI, Andrea RIZZI, Dinko ZIHER, Milan MESIC, Ivaylo ELENKOV
  • Publication number: 20240166605
    Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
    Type: Application
    Filed: January 2, 2024
    Publication date: May 23, 2024
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro FALCHI, Emilio LUTERO, Emanuele FERRARI, Fausto PIVETTI, Rocco BUSSOLATI, Edoardo MARIANI, Orsola VECCHI, Erhard BAPPERT, Caterina VENTRICI
  • Patent number: 11981639
    Abstract: The present invention relates to a process for the preparation of compounds endowed with phosphodiesterase (PDE4) inhibitory activity having formula (I). The invention also relates to the process for the isolation by crystallization of the compound (I) and to its use for the preparation of pharmaceutical compositions for inhalation in combination with suitable carriers or vehicles. The present invention also relates to solvates and crystal forms of a compound of formula (I). The synthesized product is suitable for use in pharmaceutical applications for instance in the treatment of respiratory diseases.
    Type: Grant
    Filed: May 6, 2022
    Date of Patent: May 14, 2024
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Alessandro Falchi, Emilio Lutero, Emanuele Ferrari, Fausto Pivetti, Rocco Bussolati, Edoardo Mariani, Orsola Vecchi, Erhard Bappert, Caterina Ventrici
  • Publication number: 20240116947
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Paolo RONCHI, Matteo BIAGETTI, Sara GUARIENTO, Claudio FIORELLI
  • Publication number: 20240116948
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: December 20, 2021
    Publication date: April 11, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniele PALA, Daniela PIZZIRANI, Paolo BRUNO, Matteo BIAGETTI, Paolo RONCHI, Sara GUARIENTO, Barbara BERTANI, Donatella RESCIGNO
  • Publication number: 20240092790
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
  • Publication number: 20240092791
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME, David Edward CLARK
  • Publication number: 20240092792
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 21, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Christine EDWARDS, Adele Elisa PASQUA, Prashant Bhimrao KAPADNIS, Arnaud Jean Francois Auguste CHEGUILLAUME
  • Publication number: 20240082223
    Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are dihydrofuropyridine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
    Type: Application
    Filed: December 13, 2021
    Publication date: March 14, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Fabio RANCATI, Alessandro ACCETTA, Anna Maria CAPELLI, Daniele PALA, Roberta MAZZUCATO, Christine EDWARDS, Adele Elisa PASQUA
  • Publication number: 20240025880
    Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are amino quinazoline derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 25, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Daniela PIZZIRANI, Daniele PALA, Paolo RONCHI, Sara GUARIENTO, Charles BAKER-GLENN, Hervé VAN DE POËL, Kim Louise HIRST
  • Publication number: 20240018122
    Abstract: The present invention relates to a compound of general formula (I) inhibiting the transforming growth factor-? (TGF-?) type I receptor (ALK5), methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of diseases or conditions associated with a dysregulation of ALK5 signaling pathway in a mammal.
    Type: Application
    Filed: July 14, 2021
    Publication date: January 18, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Daniela PIZZIRANI, Matteo BIAGETTI, Paolo RONCHI, Paolo BRUNO, Sara GUARIENTO, Barbara BERTANI, Daniele PALA, Alessio BARILLI
  • Publication number: 20240002371
    Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: January 4, 2024
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
  • Publication number: 20230416233
    Abstract: The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are (aza)quinoline 4-amines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).
    Type: Application
    Filed: November 26, 2021
    Publication date: December 28, 2023
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Claudio FIORELLI, Paolo BRUNO, Matteo BIAGETTI, Charles BAKER-GLENN, Hervè VAN DE POËL
  • Patent number: 11844860
    Abstract: A pharmaceutical formulation for intraduodenal administration comprising melevodopa and carbidopa as active ingredients and one or more excipients. Once dispersed in an aqueous medium, melevodopa is completely dissolved, and carbidopa is present as nanoparticles.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: December 19, 2023
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Ricardo Inacio, Mark Saunders, Bhanvi Mehta, Kathrin Muehlhoelzl-Odoerfer, Isabel Sole Font, Grazia Caivano
  • Publication number: 20230364015
    Abstract: Carrier particles for dry powder formulations for inhalation having reduced electrostatic charges are prepared.
    Type: Application
    Filed: July 17, 2023
    Publication date: November 16, 2023
    Applicant: Chiesi Farmaceutici S.p.A.
    Inventors: Daniela COCCONI, Rossella Musa
  • Patent number: 11813360
    Abstract: The present invention concerns carrier particles suitable for use in dry powder formulations for inhalation. The invention also relates to processes for their preparation by spray-congealing.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: November 14, 2023
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Tomaso Guidi, Amrit Paudel, Sarah Elizabeth Zellnitz, Joana Filipa Fernandes Teixeira Pinto